|
Nov 13
|
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
|
|
Oct 9
|
INmune Bio Inc (INMB) Q2 2024 Earnings Call Highlights: Promising Advances Amid Rising Costs
|
|
Sep 30
|
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease
|
|
Sep 26
|
INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort
|
|
Jul 29
|
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
|
|
Jul 25
|
INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024
|
|
Jul 23
|
INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer
|
|
Jul 12
|
Shareholders Will Probably Be Cautious Of Increasing INmune Bio, Inc.'s (NASDAQ:INMB) CEO Compensation At The Moment
|
|
Jun 27
|
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
|
|
May 13
|
INmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call Transcript
|
|
May 12
|
INmune Bio First Quarter 2024 Earnings: EPS Misses Expectations
|
|
May 9
|
INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
|
|
May 7
|
INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9
|
|
Apr 30
|
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
|
|
Apr 29
|
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Apr 26
|
INmune Bio Independent Director Acquires 80% More Stock
|
|
Apr 25
|
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
|
|
Apr 23
|
INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
|
|
Apr 22
|
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
|
|
Apr 8
|
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
|